Short-term stake in Zosano Pharma Co. (NASDAQ:ZSAN) increases 37.0%
Zosano Pharma Co. (NASDAQ:ZSAN – Get Rating) saw a significant increase in short-term interest in March. As of March 15, there was short interest totaling 6,850,000 shares, an increase of 37.0% from the total of 5,000,000 shares as of February 28. Based on an average trading volume of 10,260,000 shares, the short interest ratio is currently 0.7 days.
A number of research companies have weighed in on ZSAN. StockNews.com began covering Zosano Pharma shares in a research note on Saturday. They issued a “sell” rating on the stock. BTIG Research upgraded Zosano Pharma shares from a “buy” rating to a “neutral” rating in a Wednesday, February 23 research note.
Zosano Pharma shares opened at $0.21 on Wednesday. Zosano Pharma has a 52-week minimum of $0.11 and a 52-week maximum of $1.30. The stock has a market capitalization of $35.18 million, a price-earnings ratio of -0.77 and a beta of 2.95. The company has a fifty-day moving average of $0.26 and a 200-day moving average of $0.49.
Zosano Pharma (NASDAQ:ZSAN – Get Rating) last reported quarterly earnings data on Thursday, March 17. The biotech company reported ($0.06) earnings per share (EPS) for the quarter, missing Zacks’ consensus estimate of ($0.05) by ($0.01). Zosano Pharma had a negative net margin of 3,812.10% and a negative return on equity of 80.12%. On average, analysts predict that Zosano Pharma will post -0.22 earnings per share for the current year.
Institutional investors and hedge funds have recently changed their positions in the company. Morgan Stanley strengthened its position in Zosano Pharma by 954.9% in the 1st quarter. Morgan Stanley now owns 45,879 shares of the biotech company valued at $57,000 after buying an additional 41,530 shares during the period. LPL Financial LLC strengthened its position in Zosano Pharma by 95.7% during the 3rd quarter. LPL Financial LLC now owns 58,700 shares of the biotech company valued at $42,000 after purchasing an additional 28,700 shares during the period. Millennium Management LLC purchased a new stake in Zosano Pharma stock in Q2 for a value of approximately $65,000. Citadel Advisors LLC raised its position in Zosano Pharma shares by 263.9% in the third quarter. Citadel Advisors LLC now owns 146,166 shares of the biotech company worth $105,000 after purchasing an additional 105,999 shares during the period. Finally, Barclays PLC increased its position in Zosano Pharma shares by 50.0% in the 3rd quarter. Barclays PLC now owns 300,000 shares of the biotech company worth $216,000 after buying an additional 100,000 shares during the period. 10.57% of the shares are held by institutional investors and hedge funds.
About Zosano Pharma (Get a rating)
Zosano Pharma Corp. is a clinical-stage biopharmaceutical company, focused on the development of human pharmaceuticals. The Company is focused on providing rapid systemic delivery of therapeutics to patients using a proprietary intracutaneous microneedle system. It offers Qtrypta, a formulation of zolmitriptan administered using the intracutaneous microneedle system.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Zosano Pharma right now?
Before you consider Zosano Pharma, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Zosano Pharma was not on the list.
Although Zosano Pharma currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here